Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial
暂无分享,去创建一个
E. Antman | M. Nieminen | R. Giugliano | E. Braunwald | S. Murphy | M. Mercuri | C. Ruff | J. Steffel | H. Lanz | R. Hamershock | N. Peterson | Nancy Peterson
[1] A. Camm,et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[2] J. Healey,et al. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2) , 2018, European heart journal.
[3] E. Antman,et al. Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial , 2018, Thrombosis and Haemostasis.
[4] G. Lip,et al. Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[5] T. Steiner,et al. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis , 2017, The New England journal of medicine.
[6] D. Adams. Idarucizumab for Dabigatran Reversal Full Cohort Analysis , 2017 .
[7] S. Connolly,et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. , 2016, The New England journal of medicine.
[8] D. Xavier,et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. , 2014, Blood.
[9] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[10] Atul Verma,et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. , 2013, The New England journal of medicine.
[11] S. Yusuf,et al. Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial , 2012, Circulation.
[12] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[13] D Bergqvist,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.
[14] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.